Portola Pharmaceuticals

📍 South San Francisco, United States🗓 Founded 2003👥 57 employees💰 Last funded Mar 2014
Pharmaceutical Manufacturing🌐 portola.com
Website LinkedIn
We are focused on the discovery, development and commercialization of novel therapeutics that could significantly advance the fields of thrombosis and other hematologic conditions. The Companys first two commercialized products are Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo], marketed in Europe as Ondexxya® (andexanet alfa), and Bevyxxa® (betrixaban). The company also is advancing cerdulatinib, an investigational SYK/JAK inhibitor being developed for the treatment of hematologic cancers. We are continuing to explore new discoveries that impact how serious blood-related disorders are treated and expanding the potential impact of our existing portfolio of medicines.
2
Total investors
1
Early stage
0
Mid stage
0
Late stage
2003
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
2
Frequently asked questions
Who invested in Portola Pharmaceuticals?
Portola Pharmaceuticals has 2 investors on record on gritt.io, including 1 early-stage backers.
When did Portola Pharmaceuticals last raise funding?
The most recent investment in Portola Pharmaceuticals recorded on gritt.io was in March 2014.
When was Portola Pharmaceuticals founded?
Portola Pharmaceuticals was founded in 2003.
What industry is Portola Pharmaceuticals in?
Portola Pharmaceuticals operates in Pharmaceutical Manufacturing. Find similar Pharmaceutical Manufacturing investors on gritt.io.
Where is Portola Pharmaceuticals based?
Portola Pharmaceuticals is headquartered in South San Francisco, United States.